Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 11 Neoplasm Metastasis 4 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Ovarian Neoplasms 2 Recurrence 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Neuroma, Acoustic 1 Neurofibromatosis 2 1 Neoplasms 1 Meningioma 1 Malignant Female Reproductive System Neoplasm 1 Lymphoma 1 Leukemia 1 Inflammatory Breast Neoplasms 1 Hemangiosarcoma 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Fallopian Tube Neoplasms 1 Ependymoma 1 Endometrial Neoplasms 1 Disease Progression 1 Disease 1 Colonic Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Lobular 1 Breast Cancer With Brain Metastasis 1 Brain Neoplasms 1 Biliary Tract Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 9 Cyclophosphamide 7 X-Rays 6 Temozolomide 6 Specimen Handling 6 Phantoms, Imaging 6 Biopsy 6 Nuclear Medicine Department, Hospital 5 Etoposide 5 Nivolumab 4 Bevacizumab 4 Radiation 3 Irinotecan 3 Automobiles 3 ulixertinib 2 tipifarnib 2 tazemetostat 2 selpercatinib 2 palbociclib 2 olaparib 2 lutetium Lu 177 dotatate 2 larotrectinib 2 ivosidenib 2 etoposide phosphate 2 erdafitinib 2 ensartinib 2 abemaciclib 2 Watchful Waiting 2 Radiotherapy 2 ONC206 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ependymoma × neratinib × 1 year × Clear all

NCT04374305 2026-05-06

INTUITT-NF2

Massachusetts General Hospital

Phase 2 Recruiting

Ependymoma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡